GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

CRNX · Dec 31, 2025

Crinetics Pharmaceuticals, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001658247-26-000012General Corporate
Capex intensity37thOwn-history percentile · N=19
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

74.87% · OPTIONAL · VALID

Operating cash generation58thOwn-history percentile · N=19
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-4910.63% · OPTIONAL · VALID

Revenue growth100thOwn-history percentile · N=15
Evidence method

Yoy · gp.fundamentals.revenue

640.71% · CORE · VALID

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

26.27% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

86.02% · CORE · NOT_ENOUGH_HISTORY

Operating margin55thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-6714.77% · CORE · VALID

R&D intensity45thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

4314.68% · OPTIONAL · VALID

SBC intensity45thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

1182.74% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History14 statesSelf-history eligible
Sep 30, 20190/6 normalizedLevel 3Dec 31, 20190/6 normalizedLevel 3Mar 31, 20200/6 normalizedLevel 3Dec 31, 20200/6 normalizedLevel 3Mar 31, 20235/6 normalizedLevel 3Jun 30, 20236/6 normalizedLevel 3Sep 30, 20236/6 normalizedLevel 3Mar 31, 20246/6 normalizedLevel 3Jun 30, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Dec 31, 20256/8 normalizedLevel 3Mar 31, 20266/8 normalizedLevel 3Jun 30, 20266/8 normalizedLevel 4
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
603.50%
Current
74.87%
Delta
-528.63%
Cash Generation Increased
Previous
-77425.17%
Current
-4910.63%
Delta
72514.55%
Profitability Increased
Previous
-99710.49%
Current
-6714.77%
Delta
92995.72%
R And D Intensity Decreased
Previous
63261.54%
Current
4314.68%
Delta
-58946.86%
Sbc Intensity Decreased
Previous
15875.52%
Current
1182.74%
Delta
-14692.78%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · CRNX Fundamental State →Transitioned To · CRNX CAPEX_INTENSITY_DECREASED →Transitioned To · CRNX CASH_GENERATION_INCREASED →Transitioned To · CRNX PROFITABILITY_INCREASED →Transitioned To · CRNX R_AND_D_INTENSITY_DECREASED →Transitioned To · CRNX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.